Tyra Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	17.43	15.92	5.65	2.09	1.33
Research & Development	62.52	43.01	20.64	7.2	1.79
Operating Expenses	79.95	58.93	26.29	9.3	3.12
Operating Income	-79.95	-58.93	-26.29	-9.3	-3.12
Interest Expense / Income	0	0	0	0	0
Other Expense / Income	-10.81	-3.6	0.01	0.04	0.94
Pretax Income	-69.13	-55.33	-26.29	-9.34	-4.07
Net Income	-69.13	-55.33	-26.29	-9.34	-4.07
Shares Outstanding (Basic)	43	42	14	2	1
Shares Outstanding (Diluted)	43	42	14	2	1
Shares Change	1.96%	203.94%	793.58%	51.14%	-
EPS (Basic)	-1.62	-1.32	-1.91	-6.05	-3.98
EPS (Diluted)	-1.62	-1.32	-1.91	-6.05	-3.98
Free Cash Flow	-50.91	-50.84	-24.39	-8.08	-2.64
Free Cash Flow Per Share	-1.19	-1.21	-1.77	-5.24	-2.58
EBITDA	-68.78	-55.03	-26.15	-9.29	-4.06
Depreciation & Amortization	0.35	0.3	0.14	0.05	0.01
EBIT	-69.13	-55.33	-26.29	-9.34	-4.06

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).